Organogenesis Holdings (FRA:2PQ) Total Equity: €329.9 Mil (As of Mar. 2026)


FRA:2PQ Organogenesis Holdings Inc FRA:2PQ
65 GF Score
Price €2.06
GF Value €2.68
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Organogenesis Holdings Total Equity?

Organogenesis Holdings FRA:2PQ -2.83% 65 Total Equity is €329.9 Mil as of Mar. 2026. GuruFocus rates FRA:2PQ with a GF Score™ of 65/100 and a GF Value™ of €2.68 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Organogenesis Holdings's total equity for the quarter that ended in Mar. 2026 was €329.9 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Organogenesis Holdings Total Equity Historical Data

* Premium members only.

The historical data trend for Organogenesis Holdings's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Organogenesis Holdings Total Equity Chart

Organogenesis Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 213.58 250.79 255.53 367.98 370.57

Organogenesis Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 340.46 313.18 328.85 370.57 329.87
FRA:2PQ
65GF Score
Organogenesis Holdings Inc FRA:2PQ
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Organogenesis Holdings Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Organogenesis Holdings's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=511.315-140.749
=370.6

Organogenesis Holdings's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=449.793-119.928
=329.9

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of €329.9 Mil mean?
Organogenesis Holdings (FRA:2PQ) has a Total Equity of €329.9 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Organogenesis Holdings and its competitors.
Is Organogenesis Holdings' Total Equity too high?
Organogenesis Holdings' current Total Equity is €329.9 Mil. Overall, Organogenesis Holdings has a GF Score™ of 65/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Organogenesis Holdings' Total Equity compare to TKNO and AKBA?
Organogenesis Holdings' Total Equity of €329.9 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Organogenesis Holdings and its competitors. Organogenesis Holdings's current Total Equity is €329.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Organogenesis Holdings stock overvalued right now?
Based on GuruFocus' analysis, Organogenesis Holdings (FRA:2PQ) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.68, compared to a current price of €2.06 — trading 23.1% below its estimated fair value. The current Total Equity is €329.9 Mil. Organogenesis Holdings' overall GF Score™ is 65/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Organogenesis Holdings (FRA:2PQ), the current Total Equity is €329.9 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Organogenesis Holdings (FRA:2PQ) Overvalued in 2026?

Based on GuruFocus' analysis, Organogenesis Holdings stock appears to be undervalued. The current stock price of €2.06 is trading 23.1% below its estimated GF Value™ of €2.68. GuruFocus considers Organogenesis Holdings to be Modestly Undervalued.

Key valuation signals for FRA:2PQ:

  • Total Equity: €329.9 Mil
  • GF Value™: €2.68 vs. price of €2.06 (23.1% below fair value)
  • GF Score™: 65/100 with 5 warning signs

No single metric tells the full story. See the FRA:2PQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Organogenesis Holdings Business Description

Other Exchanges ORGO:USA
Address 85 Dan Road, Canton, MA, USA, 02021
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
65GF Score

Get the complete analysis for FRA:2PQ

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.06
Price
€2.68
GF Value